Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2025-3431

Published: 2025

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Maximilian Stahl, Jan Philipp Bewersdorf, Rahul Vedula, Yiwen Liu, H. Moses Murdock, Harrison Tsai, Evan Chen, Benjamin Rolles, Nikolai Podoltsev, Lourdes Mendez, Luca Lanino, Alain Mina, Luis E. Aguirre, Mikkael Sekeres, Lionel Ades, R. Coleman Lindsley, Amer Zeidan

Blood (2025) 146 (Supplement 1): 5651.

https://doi.org/10.1182/blood-2025-5651

Published: 2025

Journal Articles

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Rahul Vedula, Hannah Karp, Danielle Morrow, Andrew Gehrke, Yiwen Liu, Ellen Weisberg, Carter Lombardi, Rebecca Leonard, Ilene Galinsky, Jacqueline Garcia, Marlise Luskin, Maximilian Stahl, Martha Wadleigh, Eric Winer, Daniel Deangelo, James Griffin, Richard Stone, R. Coleman Lindsley

Blood (2025) 146 (Supplement 1): 3265.

https://doi.org/10.1182/blood-2025-3265

Published: 2025

Journal Articles

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Andrew M. Brunner, Yiwen Liu, Rupa Narayan, Michelle Hyunju Lee, Philip C. Amrein, Hanno Hock, Gabriela S. Hobbs, Donna S. Neuberg, Timothy Aaron Graubert, Amir T. Fathi

Blood (2024) 144 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2024-196718

Published: 2024

Journal Articles

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1508.

https://doi.org/10.1182/blood-2024-207045

Published: 2024

Journal Articles

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Blood (2024) 144 (Supplement 1): 2947.

https://doi.org/10.1182/blood-2024-205581

Published: 2024

Journal Articles

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Josh Zhang, Shai O. Shimony, Yiwen Liu, Eno Inyang, Evan C. Chen, Luis E. Aguirre, Rebecca P. Bystrom, Benjamin Rolles, Richard M. Stone, Daniel J. DeAngelo, Emily Tiao, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 5175.

https://doi.org/10.1182/blood-2024-200358

Published: 2024

Journal Articles

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Blood (2024) 144 (Supplement 1): 4267.

https://doi.org/10.1182/blood-2024-202744

Published: 2024

Journal Articles

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Chi-Joan How, Yiwen Liu, Kathleen Gallagher, Emma K Logan, Ann Mullally, Donna S. Neuberg, Thomas Reardon, Alyssa Watson, Daniel J. DeAngelo, Rushad Patell, Gabriela S. Hobbs

Blood (2024) 144 (Supplement 1): 6644.

https://doi.org/10.1182/blood-2024-194126

Published: 2024

Journal Articles

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Andrew M. Brunner, Yiwen Liu, Jacqueline S. Garcia, Lourdes Mendez, Catherine Gutierrez, Philip C. Amrein, Rupa Narayan, Rahul Vedula, Donna S. Neuberg, Marcio Andrade-Campos, Simon Smith, Richard M Stone, Amir T. Fathi, Matthew J. Walter, Timothy Aaron Graubert, Meagan Jacoby

Blood (2024) 144 (Supplement 1): 1833.

https://doi.org/10.1182/blood-2024-195793

Published: 2024

Journal Articles

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Blood (2024) 144 (Supplement 1): 4256.

https://doi.org/10.1182/blood-2024-200876

Published: 2024

Journal Articles

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Blood (2024) 144 (Supplement 1): 4580.

https://doi.org/10.1182/blood-2024-198284

Published: 2024

Journal Articles

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Blood (2024) 144 (Supplement 1): 4281.

https://doi.org/10.1182/blood-2024-204467

Published: 2024

Journal Articles

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 772.

https://doi.org/10.1182/blood-2023-190832

Published: 2023

Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1589.

https://doi.org/10.1182/blood-2023-174283

Published: 2023

Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Blood (2023) 142 (Supplement 1): 2964.

https://doi.org/10.1182/blood-2023-174285

Published: 2023

Journal Articles

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Benjamin Rolles, Cilomar Martins De Oliveira Filho, Julia Keating, Marlise R. Luskin, Daniel J. DeAngelo, Coleman Lindsley, Annette S. Kim, Jessica Hem, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Joan How, Anna E. Marneth, Yiwen Liu, Martin J. Aryee, Harrison K. Tsai, Maximilian Stahl, Ann Mullally

Blood (2023) 142 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2023-185024

Published: 2023

Journal Articles

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

Blood (2023) 142 (Supplement 1): 999.

https://doi.org/10.1182/blood-2023-187519

Published: 2023

Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl

Blood (2023) 142 (Supplement 1): 1478.

https://doi.org/10.1182/blood-2023-172763

Published: 2023

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Validation of the international working group (IWG) 2023 criteria for clinical benefit in higher risk Myelodysplastic Syndromes (HR-MDS) using a large, international, randomized Phase 3 clinical trial dataset

Temporal multiomic profiling reveals intrinsic resistance mechanisms to ERK inhibition in relapsed Acute Myeloid Leukemia

Safety and Activity of the TIM3 Inhibitor Sabatolimab in Patients with Lower-Risk Myelodysplastic Syndromes

Venetoclax-Based Therapy Versus Intensive Chemotherapy Followed By Allogeneic-Stem Cell Transplantation for High-Risk Elderly Acute Myeloid Leukemia

The Prognostic and Predictive Value of RUNX1 Mutations in Newly Diagnosed Acute Myeloid Leukemia - an International Multicenter Cohort Study

Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy

Comparative Analysis of Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients Harboring Very-High Risk Cytogenetics

Trial-in-Progress: A Phase 2 Study of Ruxolitinib in Low-Risk Essential Thrombocythemia and Polycythemia Vera Patients with High Symptom Burden

Clinical Activity and Safety of the Oral ATR Inhibitor Ceralasertib (AZD6738) in Patients with MDS or CMML after Prior HMA Therapy

Randomized Phase II Trial of Dendritic Cell/AML Fusion Cell Vaccination Compared to Standard of Care Therapy in AML CR1

Dual Bclxl and BCL2 Inhibition with Navitoclax (NAV), Venetoclax (VEN), and Decitabine (DEC) for Advanced Myeloid Neoplasms (MN): Safety and Biological Activity in a Phase 1 Study

Outcomes with HMA Plus Venetoclax Vs Intensive Chemotherapy in AML Patients with Chromosome 5 and 7 Abnormalities

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

TP53 mutations and Their Impact on Survival in Patients with Myeloproliferative Neoplasms

Subunit-Specific Analysis of Cohesin-Mutant Myeloid Malignancies Reveals Distinct Ontogeny and Outcomes

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only